Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising eczema treatment for kids shows safety and symptom relief

NCT ID NCT04921345

Completed Symptom relief Sponsor: Galderma R&D Source: ClinicalTrials.gov ↗

First seen May 29, 2026 · Last updated Jun 12, 2026 · Updated 3 times

Summary

This study tested a drug called nemolizumab in 109 children aged 2 to 11 with moderate-to-severe eczema. The goal was to see how the drug works in the body, if it is safe, and if it helps improve skin symptoms. The children received the drug and were monitored for up to 52 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Galderma Investigational Site #5495

    Rzeszów, 35-055, Poland

  • Galderma Investigational Site #5531

    Szeged, 6720, Hungary

  • Galderma Investigational Site #5570

    Lodz, 90-265, Poland

  • Galderma Investigational Site #5896

    Esplugues de Llobregat, 0850, Spain

  • Galderma Investigational Site #6147

    Budapest, 1036, Hungary

  • Galderma Investigational Site #6218

    Hellerup, 2900, Denmark

  • Galderma Investigational Site #6237

    Ostrowiec Świętokrzyski, 27-400, Poland

  • Galderma Investigational Site #6261

    Wroclaw, 51-685, Poland

  • Galderma Investigational Site #6262

    Warsaw, 02-953, Poland

  • Galderma Investigational Site #78218-3128

    San Antonio, Texas, 78218-3128, United States

  • Galderma Investigational Site #8092

    Louisville, Kentucky, 40217-1444, United States

  • Galderma Investigational Site #8142

    Indianapolis, Indiana, 46250-2041, United States

  • Galderma Investigational Site #8155

    Troy, Michigan, 48084-5260, United States

  • Galderma Investigational Site #8206

    Norman, Oklahoma, 73069-6301, United States

  • Galderma Investigational Site #8242

    Brooklyn, New York, 11203-2012, United States

  • Galderma Investigational Site #8255

    Philadelphia, Pennsylvania, 19103-4708, United States

  • Galderma Investigational Site #8560

    West Bloomfield, Michigan, 48322, United States

  • Galderma Investigational Site #8636

    Fountain Valley, California, 92708-3701, United States

  • Galderma Investigational Site #9929

    Coral Gables, Florida, 92083-6031, United States

  • Galderma Investigational Site #9930

    Vista, California, 92083-6031, United States

  • Galderma Investigational Site #9931

    Beaumont, Texas, 77706-3061, United States

  • Galderma Investigational Site #9937

    San Diego, California, 92123-2746, United States

  • Galderma Investigational Site #9938

    New York, New York, 10032-3729, United States

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE-TO-SEVERE ATOPIC DERMATITIS